Hay Ian D, Lee Robert A, Reading Carl C, Charboneau J William
Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
J Endocr Soc. 2024 Feb 27;8(5):bvae037. doi: 10.1210/jendso/bvae037. eCollection 2024 Mar 12.
Results of ethanol ablation (EA) for controlling neck nodal metastases (NNM) in adult patients with papillary thyroid carcinoma (APTC) beyond 6 months have rarely been reported. We now describe outcome results in controlling 71 NNM in 40 node-positive stage I APTC patients followed for 66 to 269 months.
All 40 patients were managed with bilateral thyroidectomy and radioiodine therapy and followed with neck ultrasound (US) for >48 months after EA. Cumulative radioiodine doses ranged from 30 to 550 mCi; pre-EA 27 patients (67%) had 36 additional neck surgeries. Cytologic diagnosis of PTC in 71 NNM selected for EA was confirmed by US-guided biopsy. EA technique and follow-up protocol were as previously described.
The 40 patients had 1 to 4 NNM; 67/71 NNM (94%) received 2 to 4 ethanol injections (total median volume 0.8 cc). All ablated 71 NNM shrank (mean volume reduction of 93%); nodal hypervascularity was eliminated. Thirty-eight NNM (54%) with initial volumes of 12-1404 mm (median 164) disappeared on neck sonography. Thirty-three hypovascular foci from ablated NNM (pre-EA volume range 31-636 mm; median 147) were still identifiable with volume reductions of 45% to 97% observed (median 81%). There were no complications and no postprocedure hoarseness. Final results were considered to be ideal or near ideal in 55% and satisfactory in 45%. There was no evidence of tumor regrowth after EA.
Our results demonstrate that for patients with American Joint Committee on Cancer stage I APTC, who do not wish further surgery or radioiodine, and are uncomfortable with active surveillance, EA can achieve durable control of recurrent NNM.
关于乙醇消融(EA)用于控制成年乳头状甲状腺癌(APTC)患者颈部淋巴结转移(NNM)超过6个月的结果鲜有报道。我们现描述40例I期淋巴结阳性APTC患者71处NNM接受EA治疗并随访66至269个月的结局结果。
所有40例患者均接受双侧甲状腺切除术和放射性碘治疗,并在EA后接受颈部超声(US)检查超过48个月。累积放射性碘剂量为30至550 mCi;EA前27例患者(67%)还接受了36次额外的颈部手术。经US引导活检证实71处选择进行EA的NNM为PTC的细胞学诊断。EA技术和随访方案如前所述。
40例患者有1至4处NNM;67/71处NNM(94%)接受了2至4次乙醇注射(总中位体积0.8 cc)。所有71处被消融的NNM均缩小(平均体积缩小93%);淋巴结高血管化消失。38处初始体积为12 - 1404 mm(中位值164)的NNM在颈部超声检查中消失。33个来自被消融NNM的低血管灶(EA前体积范围31 - 636 mm;中位值147)仍可识别,观察到体积缩小45%至97%(中位值81%)。无并发症发生,术后也无声音嘶哑。最终结果被认为理想或接近理想的占55%,满意的占45%。EA后无肿瘤复发迹象。
我们的结果表明,对于美国癌症联合委员会I期APTC患者,那些不希望进一步手术或放射性碘治疗且对主动监测感到不适的患者,EA可实现对复发性NNM的持久控制。